Thompson, Anne
March 2007
Daily Variety;3/30/2007, Vol. 294 Issue 65, p1
Trade Publication
The article reports that Michael London of Groundswell productions has closed a financing agreement with global investment firm TPG-Axon Capital. The plans of Groundswell to finance and produce four to five films a year are presented. The article also announces that the company has appointed Peter Herzig as chief financial officer and Cotty Chubb as executive vice president of production.


Related Articles

  • Comerica enables Groundswell move. DiOrio, Carl; Kilday, Gregg // Hollywood Reporter;1/25/2010, Vol. 413 Issue 5, p2 

    The article reports on the completion of the management-led restructuring Groundswell Productions by chief executive officer (CEO) Michael London.

  • France inks pic pact.  // Daily Variety;05/18/2001, Vol. 271 Issue 57, p6 

    Focuses on the agreement between Imcine, a Mexican film institute and Unifrance on an informal movie co-production deal in Mexico.

  • 'Final' word for London.  // Daily Variety;11/22/2011, Vol. 313 Issue 37, p1 

    The article reports on the comedy film project of Michael London and his production company entitled "Final Girls," which will be directed by Todd Strauss-Schulson.

  • Pressure for Triad buyout. Galloro, Vince // Modern Healthcare;2/5/2007, Vol. 37 Issue 6, p14 

    The article reports on the plan of hedge fund TPG-Axon Capital Management to nominate candidates to be directors of Plano, Texas-based Triad, as stated on its securities filing. The fund also revealed that it has increased its stake in the firm. A group of funds led by TPG-Axon Capital purchased...

  • Lilly taps hedge fund. Wall, J. K. // Indianapolis Business Journal;8/11/2008, Vol. 29 Issue 23, p1 

    The article reports on the joint ventures of Eli Lilly and Co. and TPG-Axon Capital in developing a new treatment for Alzheimer's disease in Indianapolis, Indiana. Eli has tapped TPG-Axon to help them in the drug development. TPG-Axon has agreed to provide $325 million for the exorbitant...

  • CV Therapeutics Banks $175M in Royalties Deal for Lexiscan. Young, Donna // BioWorld Today;4/17/2008, Vol. 19 Issue 75, p1 

    The article reports on the venture capital received by CV Therapeutics from investment firm TPG-Axon Capital in April 2008. Said capital is for exclusive rights to 50 percent of royalties on North American sales of Lexiscan injection. The drug, which was approved by the U.S. Food and Drug...

  • Subprime Lender Lines Up Funds to Build Portfolio. Padilla, Mathew // Orange County Business Journal;8/8/2005, Vol. 28 Issue 32, p3 

    The article reports that Resmae Financial Corp., a subprime lender in Brea, has received $100 million in financing-its second big cash infusion since its founding two years ago. Resmae Financial Corp. plans to use the money to build a $1 billion portfolio of loans. The company funds home loans...

  • CV Therapeutics adds $175 million with royalties deal for Lexiscan.  // Cardiovascular Devices & Drugs;Apr2008, Vol. 14 Issue 4, p13 

    The article reports on the increase in the shares of CV Therapeutics by 17.6% following the news that the firm received $175 million in cash from investment firm TPG-Axon Capital in exchange for rights to 50% royalties on North American sales of Lexiscan injection. It is inferred that Lexisca's...

  • The Morning Brief: Kleinheinz to Shutter; Griffin's $15m Condo.  // AR Magazine;Nov2012, Vol. 4 Issue 3, p57 

    This section offers news briefs concerning hedge funds as of November 2012. John Kleinheinz decided to shut down the value-focused Kleinheinz Capital Partners, which has an estimated assets of 2 billion dollars, after a period of poor performance. Ken Griffin of Citadel purchased a penthouse on...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics